Aardvark Therapeutics, Inc. Common Stock AARD Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $0— | $0— | —— | —— | —— | ||
| $57.75M+18.0% | $48.94M+14.6% | $42.7M+29.3% | $33.03M+38.1% | $23.91M+37.7% | ||
| $16.97M+23.1% | $13.79M+28.0% | $10.77M+37.5% | $7.83M+9.4% | $7.16M+34.9% | ||
| $74.72M+19.1% | $62.73M+17.3% | $53.47M+30.9% | $40.86M+31.4% | $31.08M+36.4% | ||
| -$74.72M-19.1% | -$62.73M-17.3% | -$53.47M-30.9% | -$40.86M-31.4% | -$31.08M-36.4% | ||
| $4.85M-5.5% | $5.13M+9.3% | $4.7M+11.3% | $4.22M+25.5% | $3.36M+53.1% | ||
| -$69.87M-21.3% | -$57.59M-18.1% | -$48.77M-33.1% | -$36.64M-32.2% | -$27.72M-34.6% | ||
| -$3.21-9.6% | -$2.93+31.9% | -$4.30+6.5% | -$4.60+13.4% | -$5.31-3.1% | ||
| -$74.68M-19.1% | -$62.69M-17.3% | -$53.44M-30.9% | -$40.83M-31.4% | -$31.07M-36.4% | ||
| -$74.72M-19.1% | -$62.73M-17.3% | -$53.47M-30.9% | -$40.86M-31.4% | -$31.08M-36.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Aardvark Therapeutics, Inc. Common Stock profitable?
- Aardvark Therapeutics, Inc. Common Stock is not currently profitable: it reported a net loss of $69.9M over the trailing twelve months.
- What is Aardvark Therapeutics, Inc. Common Stock's earnings per share?
- Aardvark Therapeutics, Inc. Common Stock's diluted EPS over the trailing twelve months is $-3.21.
- Where does Aardvark Therapeutics, Inc. Common Stock's income statement data come from?
- Every line is extracted from Aardvark Therapeutics, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.